On April 15, 2026, the U.S. Food and Drug Administration (“FDA”) announced that it will convene a public meeting of the Pharmacy Compounding ...
On May 1, the US Food and Drug Administration (FDA) announced that it is proposing to exclude semaglutide, tirzepatide, and liraglutide from the ...
The FDA has proposed excluding weight-loss drugs, such as Ozempic/Wegovy and Zepbound from a key compounding list, ...
The US Food and Drug Administration (FDA) late Friday issued revised versions of two final guidance documents explaining the use of bulk drug substances in compounding and clarifying that the agency ...
If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines unless they appear on the FDA's drug shortage list.
Compounded semaglutide, tirzepatide and liraglutide could be harder to come by starting this summer, if the U.S. Food and ...
By Mariam Sunny April 30 (Reuters) - The U.S. Food and Drug Administration on Thursday proposed excluding Novo Nordisk and Eli Lilly's weight-loss drugs from a key compounding list, potentially ...
The FDA has moved to exclude semaglutide, tirzepatide and liraglutide -- which are in several popular weight loss drugs -- from its 503B bulks list.
In April, FDA detailed its priorities for drug compounding in 2019, which include issuing a new proposed rule to update the list of bulk drug substances that can be used in compounding under Section ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results